Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by Wedbush in a research report issued on Thursday, Benzinga reports. They currently have a $165.00 target price on the stock. Wedbush’s target price indicates a potential upside of 96.82% from the stock’s previous close.

A number of other brokerages also recently weighed in on ORKA. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Finally, Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded down $6.10 during trading hours on Thursday, hitting $83.83. 420,106 shares of the company’s stock were exchanged, compared to its average volume of 1,098,693. The stock’s 50-day moving average is $96.79 and its 200-day moving average is $75.32. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of -41.39 and a beta of -0.34. Oruka Therapeutics has a 52 week low of $14.89 and a 52 week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This represents a 7.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 122,950 shares of company stock worth $11,528,806 over the last ninety days. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors have recently made changes to their positions in the stock. Nykredit A S acquired a new position in Oruka Therapeutics in the second quarter valued at about $29,000. Orion Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $91,000. Natural Investments LLC acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $202,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $211,000. 56.44% of the stock is owned by institutional investors and hedge funds.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.